Kyverna TherapueticsEmeryville, CA, United States
0904: KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease
Monday, November 13, 20239:00 AM – 11:00 AM PT
Disclosure information not submitted.
